Meningiom kliniske forsøg i Ohio
7 studier for Meningiom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- og 30 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT02523014A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- The Ohio State University College of Medicine (OSUCOM), Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT07428616RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. aug. 2026 · NCT07150806Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Mayfield Brain and Spine, Cincinnati
- Kettering Health, Kettering
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 22. jul. 2026 · NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererFase 1/2
Alder 4 til 39 · Alle køn · Opdateret 20. jul. 2026 · NCT05278208Cognitive Status After Removal of Skull Base Meningioma
- Ohio State University Wexner Medical Center, Columbus
RekruttererObservationsstudie
Alder 18 til 89 · Alle køn · Opdateret 22. maj 2026 · NCT04635657Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- UH Cleveland Medical Center, Cleveland
- Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 til 90 · Alle køn · Opdateret 14. maj 2026 · NCT05636618Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.